📇 Rhumatologue · LA TRONCHE · (38) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
27
27 articles ont été cités au moins 27fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 812
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
158
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
48
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire de Grenoble · Université Grenoble Alpes
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
French protocol for the diagnosis and management of hereditary angioedema.
2025ArticleLa Revue de Médecine Interne
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
2025ArticleClinical Reviews in Allergy & Immunology
Angioedema Due to Acquired C1-Inhibitor Deficiency Without Hematological Condition: A Multicenter French Cohort Study of 34 Patients
2025ArticleJournal of Allergy and Clinical Immunology: In Practice
Hereditary angioedema in children: Review and practical perspective for clinical management
2024ArticlePediatric Allergy and Immunology
Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort
2024ArticleJournal of Allergy and Clinical Immunology: In Practice
Splenectomy allows remission of angioedema with acquired C1-inhibitor deficiency associated with splenic marginal zone lymphoma
2024ArticleJournal of Allergy and Clinical Immunology: In Practice
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
2024ArticleJournal of Allergy and Clinical Immunology
Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study
2024ArticleAllergy
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL NORD - CHU38
BD DE LA CHANTOURNE, 38700 LA TRONCHE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Allergy · 2022
AbstractHereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
The World Allergy Organization journal · 2022
The Journal of allergy and clinical immunology · 2024
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The journal of allergy and clinical immunology. In practice · 2024 · Journal Article
Lahuna C, Defendi F, Bouillet L, Boccon-Gibod I, et al.
The journal of allergy and clinical immunology. In practice · 2024 · Journal Article
Petersen RS, Fijen LM, Apfelbacher C, Magerl M, et al.
The journal of allergy and clinical immunology. In practice · 2023 · Multicenter Study
Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, et al.
Medicine · 2022 · Journal Article
Simon N, Bocquet A, Boccon-Gibod I, Bouillet L
Frontiers in medicine · 2020 · Journal Article
Marceau F, Rivard GE, Gauthier JM, Binkley KE, et al.
European journal of internal medicine · 2019 · Journal Article
Javaud N, Altar A, Fain O, Reuter PG, et al.
Frontiers in medicine · 2019 · Journal Article
Wu MA, Tsvirkun D, Bureau L, Boccon-Gibod I, et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018 · Journal Article
Belbézier A, Boccon-Gibod I, Thanh AD, Fain O, et al.
European journal of dermatology : EJD · 2017 · Journal Article
Bouillet L, Boccon-Gibod I, Gompel A, Floccard B, et al.
Immunity, inflammation and disease · 2017 · Journal Article
Bouillet L, Boccon-Gibod I, Launay D, Gompel A, et al.
Journal of clinical immunology · 2017 · Case Reports
Faisant C, Du Thanh A, Mansard C, Deroux A, et al.
Frontiers in immunology · 2026 · Journal Article
Cancian M, Caballero T, Boccon-Gibod I, Buttgereit T, et al.
Allergy · 2026 · Journal Article
Farkas H, Martinez-Saguer I, Bork K, Germenis AE, et al.
Clinical reviews in allergy & immunology · 2025 · Journal Article
Zuraw BL, Bork K, Bouillet L, Christiansen SC, et al.
Orphanet journal of rare diseases · 2024 · Journal Article
Hoarau C, Maleki A, Bouillet L, Boccon-Gibod I
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022 · Journal Article
Maurer M, Magerl M, Aygören-Pürsün E, Bork K, et al.
The journal of allergy and clinical immunology. In practice · 2025 · Journal Article
Stammler R, Defendi F, Aubineau M, Bibes B, et al.
Clinical reviews in allergy & immunology · 2021 · Journal Article
Zanichelli A, Farkas H, Bouillet L, Bara N, et al.
Allergy · 2026 · Journal Article
Farkas H, Martinez-Saguer I, Bork K, Germenis AE, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2024 · Journal Article
Pagnier A, Dermesropian A, Kevorkian-Verguet C, Bourgoin-Heck M, et al.
The journal of allergy and clinical immunology. Global · 2026 · Journal Article
Buckland MS, Boccon-Gibod I, De Moreuil C, Sanges S
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021 · Case Reports
Bouillet L, Bocquet A, Belbezier A, Boccon-Gibod I
The journal of allergy and clinical immunology. In practice · 2024 · Multicenter Study
Kalmi G, Nguyen Y, Amarger S, Aubineau M, et al.
Annals of emergency medicine · 2018 · Journal Article
Javaud N, Fain O, Durand-Zaleski I, Launay D, et al.
The journal of allergy and clinical immunology. Global · 2026 · Journal Article
Buckland MS, Boccon-Gibod I, De Moreuil C, Sanges S
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2024 · Journal Article
Pagnier A, Dermesropian A, Kevorkian-Verguet C, Bourgoin-Heck M, et al.
Frontiers in immunology · 2026 · Journal Article
Cancian M, Caballero T, Boccon-Gibod I, Buttgereit T, et al.
Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
Abstract Background Hereditary angioedema (HAE) is characterized by potentially severe and life-threatening attacks of localized swelling. Prophylactic therapies are available, including attenuated androgens. Efficacy of
Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
Abstract Background Hereditary angioedema (HAE) is characterized by potentially severe and life-threatening attacks of localized swelling. Prophylactic therapies are available, including attenuated androgens. Efficacy of
Additional file 8 of Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
Additional file 8: Figure S2. Angioedema Quality of Life Questionnaire (AE-QoL) score based on ongoing use of C1 inhibitor (C1-INH) long-term prophylaxis (LTP) at lanadelumab initiation. a Ongoing C1-INH LTP before D0; b
Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
Abstract Background Hereditary angioedema (HAE) is associated with a heavy burden of illness. Objective To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program. Methods ATU requests were
Unmet needs in hereditary angioedema: an international survey of physicians
Abstract Background Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by unpredictable attacks of angioedema. MENTALIST (UnMEt Needs in herediTAry angioedema—a gLobal p
Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
Abstract Background Hereditary angioedema (HAE) is associated with a heavy burden of illness. Objective To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program. Methods ATU requests were
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
The Journal of allergy and clinical immunology · 2024 · Journal Article
Reshef A, Buttgereit T, Betschel SD, Caballero T, et al.
Allergy · 2022 · Journal Article
Maurer M, Magerl M, Betschel S, Aberer W, et al.
The World Allergy Organization journal · 2022 · Journal Article
Maurer M, Magerl M, Betschel S, Aberer W, et al.
European journal of emergency medicine : official journal of the European Society for Emergency Medicine · 2017 · Consensus Statement
Floccard B, Javaud N, Deroux A, Boccon-Gibod I, et al.